Skip to main content
. 2015 Jun 15;125(7):2707–2720. doi: 10.1172/JCI70805

Figure 5. Suppression of DAPK1 expression specifically inhibits the growth of p53-mutant ovarian and pancreatic cancer cell lines in vitro.

Figure 5

Knockdown efficiency of DAPK1 siRNA in each cell line is plotted in inserted panel (black). (A) Growth of p53-WT H1650 (lung) upon DAPK1 knockdown. (B) Growth of p53-mutated PANC-1 (pancreatic) upon DAPK1 knockdown. (C) Growth of p53-mutant SKOV-3 (ovarian) upon DAPK1 knockdown. (D) Effect of DAPK1 inhibitor in p53-WT H1650 (lung). (E) Effect of DAPK1 inhibitor in p53-mutated PANC-1 (pancreatic). (F) DAPK1 protein levels across cancer cell lines. Western blot was performed 3 times. A representative Western blot is shown. DAPK1 knockdown and cell growth experiments were performed in triplicate, with results reported as average ± SEM. *P < 0.01; **P < 0.001, 2-tailed Student’s t test.